OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
VIH55

Srivichai vejvivat PCL

Healthcare Facilities & ServicesVerified

Srivichai Vejvivat PCL maintains a strong capital structure with a low debt-to-equity ratio of 0.02, indicating minimal reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 4.64, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints. In terms of profitability, the company's return on equity (ROE) is 11.26%, and its return on assets (ROA) is 9.74%. These figures suggest that the company is generating solid returns relative to its equity and asset base, which is a positive indicator for investors. The operating margin, calculated as operating income divided by revenue, is 17.9%, indicating efficient cost management and strong operational performance. The company's revenue is primarily concentrated in its core healthcare services and biotechnology segments, with no significant geographic diversification reported in the available data. This concentration may expose the company to specific market risks, particularly in the healthcare sector, which is subject to regulatory and economic fluctuations. Looking ahead, the company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted for the current and next fiscal years. The company's capital expenditure of -194.07 million THB indicates a reduction in investment in physical assets, which could be a strategic move to preserve cash or a sign of reduced expansion plans. The company's risk profile is characterized by a low dilution potential, with no significant dilution sources identified in the available data. However, the negative net cash position after subtracting total debt is a key risk flag that investors should monitor. The company's financial flexibility and ability to meet short-term obligations are supported by its strong equity base and low debt levels. Recent events and filings do not indicate any major operational or financial disruptions for Srivichai Vejvivat PCL. The company's financial performance and strategic direction appear to be stable, with no significant changes in its business model or market position reported in the latest available data.

30-day price · VIH-0.10 (-1.1%)
Low$8.40High$9.15Close$8.85As of15 May, 00:00 UTC
Profile
CompanySrivichai vejvivat PCL
TickerVIH.BK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Srivichai Vejvivat PCL provides healthcare services and equipment, primarily operating in the biotechnology sector.

Classification. The company is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

Srivichai Vejvivat PCL maintains a strong capital structure with a low debt-to-equity ratio of 0.02, indicating minimal reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 4.64, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints. In terms of profitability, the company's return on equity (ROE) is 11.26%, and its return on assets (ROA) is 9.74%. These figures suggest that the company is generating solid returns relative to its equity and asset base, which is a positive indicator for investors. The operating margin, calculated as operating income divided by revenue, is 17.9%, indicating efficient cost management and strong operational performance. The company's revenue is primarily concentrated in its core healthcare services and biotechnology segments, with no significant geographic diversification reported in the available data. This concentration may expose the company to specific market risks, particularly in the healthcare sector, which is subject to regulatory and economic fluctuations. Looking ahead, the company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted for the current and next fiscal years. The company's capital expenditure of -194.07 million THB indicates a reduction in investment in physical assets, which could be a strategic move to preserve cash or a sign of reduced expansion plans. The company's risk profile is characterized by a low dilution potential, with no significant dilution sources identified in the available data. However, the negative net cash position after subtracting total debt is a key risk flag that investors should monitor. The company's financial flexibility and ability to meet short-term obligations are supported by its strong equity base and low debt levels. Recent events and filings do not indicate any major operational or financial disruptions for Srivichai Vejvivat PCL. The company's financial performance and strategic direction appear to be stable, with no significant changes in its business model or market position reported in the latest available data.
Key takeaways
  • Srivichai Vejvivat PCL has a strong equity base and low debt levels, contributing to a stable capital structure.
  • The company's ROE and ROA are above average, indicating efficient use of capital and assets.
  • Revenue is concentrated in the healthcare services and biotechnology segments, with no significant geographic diversification.
  • The company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted.
  • The company's liquidity position is medium, with a current ratio of 4.64, but a negative net cash position after subtracting total debt is a key risk flag.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$3.06B
Gross profit$841.1M
Operating income$547.7M
Net income$436.2M
R&D
SG&A
D&A
SBC
Operating cash flow$513.7M
CapEx-$194.1M
Free cash flow$277.9M
Total assets$4.48B
Total liabilities$602.3M
Total equity$3.87B
Cash & equivalents$430.00
Long-term debt$67.5M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$3.87B
Net cash-$67.5M
Current ratio4.6
Debt/Equity0.0
ROA9.7%
ROE11.3%
Cash conversion1.2%
CapEx/Revenue-6.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
MetricVIHActivity
Op margin17.9%5.6% medp25 -4.2% · p75 12.6%top quartile
Net margin14.2%2.8% medp25 -3.4% · p75 8.8%top quartile
Gross margin27.5%36.5% medp25 23.7% · p75 65.2%below median
CapEx / revenue-6.3%-4.9% medp25 -11.5% · p75 -2.0%below median
Debt / equity2.0%69.3% medp25 7.9% · p75 120.9%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-15 01:17 UTC#18857102
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 22:29 UTCJob: 07dc256a